A Novel Scalable Production Platform for Gene Therapy Vectors Based on Human Suspension Cell Lines

by Kerstin Hein, Simon Fradin, Helmut Kewes, Martina Graßl, and Nicole Faust
Volume 15, Issue 4 (Winter 2016/2017)

A rapid increase in the number of gene therapy trials and products has led to a comparable increase in the need for industrial production of viral gene therapy vectors such as lentiviral, adeno-associated, and adenoviral vectors. Current production systems are limited with respect to scalability and robustness. With our CAP® and CAP-T™ cell lines, we have developed a novel system for high-density suspension culture, efficient and reproducible transfection, and highly efficient production of viral vectors. By upstream process optimization, we have obtained a robust and high-density fed-batch culture system which can be scaled in any current bioreactor format. A design-of-experiments approach has been employed to optimize transient production of lentiviral vectors with significantly higher titers than can be obtained with adherent HEK293T cells...

Hein K, Fradin S, Kewes H, Graßl M, Faust N. A novel scalable production platform for gene therapy vectors based on human suspension cell lines. BioProcess J, 2017; 15(4): 8–15. https://doi.org/10.12665/J154.Faust.

Posted online February 15, 2017.